Daniel L. Hertz, PharmD, PhD

DLHertz@med.umich.edu

|  |  |
| --- | --- |
| Present Position | Research Assistant ProfessorDepartment of Clinical PharmacyUniversity of Michigan College of Pharmacy428 Church StreetAnn Arbor, MI 48109Office: (734) 763-0015Fax: (734) 763-4480 |
| Education and Training |
| **Sept 2008-****May 2013****Sept 2002-****May 2008** | University of North Carolina at Chapel HillUNC Eshelman School of PharmacyDivision of Pharmacotherapy and Experimental TherapeuticsChapel Hill, NC 27516Degree: Doctor of Philosophy (PhD) May 2013Rutgers, The State University of New JerseyErnest Mario School of PharmacyPiscataway, NJ 08854Degree: Doctor of Pharmacy (PharmD) May 2008GPA: 3.91/4.0 Summa Cum Laude |
| Licensure | New Jersey (License #28RI03227100, Inactive)North Carolina (License #20495, Inactive) |
| Professional Experience and academic appointments |
| Feb 2014-presentApril 2013-present | Affiliate member, University of Michigan Comprehensive Cancer CenterResearch Assistant ProfessorDepartment of Clinical PharmacyUniversity of Michigan College of PharmacyAnn Arbor, Michigan |
| Publications |
| 1. **Hertz DL**, Rae JM, McLeod HL. One Step at a Time: CYP2D6 Guided Tamoxifen Treatment Awaits Convincing Evidence of Clinical Validity. Pharmacogenomics (Invited Editorial, Submitted)
2. **Hertz DL**, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. British Journal of Clinical Pharmacology 2016 (In Press)
3. **Hertz DL**, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens ST, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy. Clinical Cancer Research (Accepted with Minor Revision)
4. **Hertz DL**, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DN, Henry NL, Rae JM. Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer. The Pharmacogenomics Journal (In Review)
5. **Hertz DL**, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin Jr. WJ Tamoxifen Dose Escalation in Patients with Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations without Increasing Toxicity. The Oncologist (Accepted with Minor Revision)
6. **Hertz DL**, Caram MV, Kidwell KM, Thibert JN, Gersch CL, Seewald NJ, Smerage J, Rubenfire M, Henry NL, Cooney KA, Leja M, Griggs JJ, Rae JM. Association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with anthracycline-induced cardiotoxicity. Pharmacogenomics (In Press).
7. Caram M.E.V, Guo C, **Hertz DL**, Kidwell KM, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, Van Poznak C, Cooney KA, Thibert JN, Gersch C, Seewald NJ, Banerjee M, Rae JM, Leja M, Griggs JJ. Diastolic Dysfunction in Patients Treated with Doxorubicin for Early-Stage Breast Cancer, Breast Cancer Res Treat 2016 (In Press)
8. **Hertz DL**, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM. Genotyping Concordance in DNA Extracted from Formalin-Fixed Paraffin Embedded (FFPE) Breast Tumor and Whole Blood for Pharmacogenetic Analyses. Molecular Oncology 2015 Nov;9(9):1868-76. doi: 10.1016/j.molonc.2015.07.002. Epub 2015 Jul 29. PMID: 26276228 PMCID: PMC4624024
9. Caram ME, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, Van Poznak C, Cooney KA, **Hertz DL**, Banerjee M, Griggs JJ. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Res Treat. 2015 Jul;152(1):163-72. doi: 10.1007/s10549-015-3454-8. Epub 2015 Jun 7.
10. **Hertz DL**, Rae JM, Pharmacogenetic Predictors of Response. Novel Biomarkers in the Continuum of Breast Cancer. BCRF 2015 (Book Chapter, In Press)
11. **Hertz DL**, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irivin Jr. WJ, In Vivo Assessment of the Metabolic Activity of CYP2D6 Diplotypes and Alleles. Br J Clin Pharmacol. 2015 Nov;80(5):1122-30. doi: 10.1111/bcp.12665. PMID: 25907378 PMCID: PMC4631184
12. **Hertz DL**, Rae J, Pharmacogenetics of Cancer Drugs. Annu Rev Med 2015 Jan 14; 66:65-81. PMID: 25386932
13. Patel JN**,** Jiang C, **Hertz DL**, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2014 Nov 21 doi: 10.1002/cncr.29169. PMID: 25417775 PMCID: PMC4368497
14. **Hertz DL**, Perissinotti AJ, Germline Pharmacogenetics in Oncology. Pharmacogenomics: Applications to Patient Care, Second Edition. ACCP. ISBN: 978-1-939862-09-9; 2015; (Book Chapter)
15. **Hertz DL**, Ellingrod VL, Mcinnis M, Bipolar Disorder in the Cancer Patient. Psychopharmacology in Oncology and Palliative Care: A Practice Manual, Pgs 189-202 2014, Springer http://www.springer.com/us/book/9783642401336 ISBN 978-3-642-40134-3 (Book Chapter)
16. **Hertz DL**, McLeod HL, Cancer Pharmacogenomics. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Published Online: April 8, 2015. DOI: 10.1002/3527600906.mcb.201500002
17. **Hertz DL**, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL, Genetic Heterogeneity Beyond CYP2C8\*3 Does Not Explain Differential Sensitivity to Paclitaxel-Induced Neuropathy. Breast Cancer Res Treat 2014;145(1);245-54. PMID: 24706167, PMCID: PMC4256153
18. **Hertz DL**, McLeod HL, Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology. (CCR-13-2780R) Clin Cancer Res 2014 May 15;20(10):2530-40. doi: 10.1158/1078-0432.CCR-13-2780. PMID: 24831276
19. McWhinney-Glass S\*, Winham SJ\*, **Hertz DL**, Yen-Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, and McLeod HL, Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity, Clin Cancer Res 2013 Oct 15;19(20):5769-76 doi:10.1158/1078-0432.CCR-13.0774 PMID: 23963862, PMCID: PMC3798385
20. **Hertz DL**, Germline Pharmacogenetics of Paclitaxel for Cancer Treatment, Pharmacogenomics 2013 Jul; 14(9): 1065-84. PMID: 23837481
21. **Hertz DL**, McLeod HL, Use of Pharmacogenetics for Predicting Cancer Prognosis and Treatment Exposure, Response and Toxicity, J Hum Genet 2013 Jun;58(6):346-52. PMID: 23677053
22. Krens SD, McLeod HL, **Hertz DL**, Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics 2013;14(5):555-574. PMID: 23556452, PMCID: PMC3975654
23. **Hertz DL**, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. CYP2C8\*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013 Jun;24(6):1472-8. PMID: 23413280, PMCID: PMC3660078
24. **Hertz DL**, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8\*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012 Jul;134(1):401-10. PMID: 22527101, PMCID: PMC3727245
25. **Hertz DL**, McLeod HL, Irvin WJ, Tamoxifen and CYP2D6: A Contradiction of Data (Review). Oncologist 2012;17(5):620-30. PMID: 22531359, PMCID: PMC3360902
26. **Hertz DL**, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC. Pilot Study of Rosiglitazone as an in vivo Probe of Paclitaxel Exposure, Br J Clin Pharmacol. 2012 Jul;74(1):197-200. PMID: 22680343, PMCID: PMC3394145
27. **Hertz DL**, McLeod HL, Hoskins JM. Pharmacogenetics of breast cancer therapies (Review). Breast 2009 Oct;18(suppl 3):S59-63. PMID: 19914545
 |
| AbstractsPublished Abstracts: |
| Patel JN, Jiang C, Owzar K, **Hertz DL**, Mulkey FA, Kelly WK, Halabi S, Furukawar Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Febbo PG, Kroetz DL, Carducci MA, Mahoney JF, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. A discovery analysis to identify clinical and genetic risk factors for gastrointestinal (GI) hemorrhage (HEM) in CALGB 90401 (Alliance) American Association of Clinical Research Annual Meeting April 18, 2016, New Orleans, Louisiana (Abs# 2037) **Hertz DL,** Kidwell KM, Thibert JN, Gersch CL, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak C, Rae JM. Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses. General Poster Session #352. 2015 American Society of Clinical Oncology Annual Meeting, June 1, 2015**Hertz DL**, Jiang C, Owzar K, Halabi S, Kelly WK, Mulkey FA, Patel JN, Carducci MA, Kelley MJ, Stadler WM, Mohamed M, Morris MJ, Nakamura Y, Zembutsu H, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). General Poster Session #9612. 2014 American Society of Clinical Oncology Annual Meeting, June 1, 2014**Hertz DL**, Snavely A, Evans JP, Ibrahim JG, Anderson S, Friedman K, Weck KE, Rubin P, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schartz G, Peppercorn JM, Graham ML, Canale ST, McLeod HL, Carey LA, Irvin Jr WJ, Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity? General Poster Session #561. 2014 American Society of Clinical Oncology Annual Meeting, June 2, 2014Patel JN, Jiang C, **Hertz DL**, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). Publication only #e16061. American Society of Clinical Oncology 2014 Annual Meeting Patel JN, Jiang C, **Hertz DL**, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). General Poster Session Abstract #3841. American Association of Clinical Research April 8, 2014. **Hertz DL**, Owzar K, Halabi S, Kelly WK, Zembutsu H, Jiang C, Patel NJ, Watson D, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Small EJ, Febbo PG, Nakamura Y, Kubo M, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401(ALLIANCE). J Clin oncol 31, 2013 (suppl; abstr 11053) General Poster Session, Tumor Biology, American Society of Clinical Oncology, June 3, 2013**Hertz DL**, Crona D, Talameh J, Brantley S, Roode L, Theken K, Zafir B, Hull JH. Integration of Scientific Writing into an Applied Biostatistics and SAS Programming Course for Pharmaceutical Sciences Graduate Students (Poster: P0-11, Manuscript: <http://analytics.ncsu.edu/sesug/2012/PO-11.pdf>)South East SAS Users Group 2012 Conference Oct 14, 2012**Hertz DL**, Dees EC, Motsinger-Reif AA, Drobish A, Roy S, McLeod HL, Carey LA. Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment. J Clin Oncol 30, 2012 (suppl; abstr 10515) Poster Discussion, American Society of Clinical Oncology, June 5, 2012 |
| Unpublished Abstracts: |
| Nguyen H\*, Sun D, Henry NL, **Hertz DL**,Pharmacokinetic Prediction of Paclitaxel Induced Peripheral Neuropathy. (Quantitative Pharmacology Poster Session Abs 475) American Society of Clinical Pharmacology and Therapeutics March 10, 2016. Quantitative Translational Approaches in Oncology Pre-conference March 8, 2016, ASHP Midyear Clinical Meeting Abs 7-142 December 9, 2015 **Hertz DL**, Danko W\*, Deal A, Walko CM, Flockhart DA, McLeod HL, Ibrahim JG, Irvin Jr WJ. Comprehensive assessment of the effect of genetic polymorphisms in drug metabolizing enzymes and transporters on tamoxifen activation to endoxifen. (General Poster Session Abs P5-12-06) San Antonio Breast Cancer Symposium December 11, 2015 **Hertz DL**, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. CYP3A4\*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients (General Poster Session P5-12-05) San Antonio Breast Cancer Symposium December 11, 2015Ahern TP, **Hertz DL**, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: an evaluation of the importance of loss-of-heterozygosity. (General Poster Session Abs P3-07-23) San Antonio Breast Cancer Symposium December 10, 2015.Kidwell KM, **Hertz DL**, Leyland-Jones B, Regan MM, Dowsett M, Rae JM. Analysis of the International tamoxifen pharmacogenomics consortium (ITPC) dataset shows that genotyping DNA derived from tumor does not introduce CYP2D6 genotyping error or mask an association with tamoxifen efficacy. (General Poster Session Abs P6-09-02) San Antonio Breast Cancer Symposium December 10, 2015.**Hertz DL**, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Rubin P, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Desta Z, Flockhart DA, Carey LA, Irvin WJ. CYP2D6 Intermediate metabolizers includes patient groups with distinct metabolic activity (General Poster Session, Abs P1-03-02) San Antonio Breast Cancer Symposium Dec 10, 2014.**Hertz DL**, Dees EC, Roy S, Motsinger-Reif AA, Drobish A, McLeod HL, Carey LA. Patients Carrying CYP2C8\*3 are at Increased Risk of Paclitaxel-Induced Neuropathy (Poster Discussion: PD 10-07) San Antonio Breast Cancer Symposium Dec 7, 2012**Hertz DL**, Dees EC, Motsinger-Reif AA, Drobish A, Winham S, McLeod HL, Carey LA. Breast Cancer Patients Carrying the CYP2C8\*3 Variant are More Likely to Achieve Clinical Complete Response from Neoadjuvant Paclitaxel Treatment (Poster Discussion: PD 07-10) San Antonio Breast Cancer Symposium Dec 11, 2010\*Denotes PharmD Investigations StudentResearch Funding |
| ACTIVE U050294 (PI: Daniel L Hertz) 12/1/2015-11/30/2016MICHR SEED $5,000Title of Project: Frequency and Causes of Patient Underreporting of Peripheral NeuropathyThe major goals of this project are to document the discrepancy between patient-reported and clinician documented peripheral neuropathy and to identify patient-specific attitudes and beliefs that are associated with non-disclosure of neuropathy during paclitaxel treatment. Role: PI (no effort)N018819 (PI: James M. Rae) 10/1/2015-9/30/2016Breast Cancer Research Foundation $250,000Title of Project: Pharmacogenomic Predictors of Breast Cancer Endocrine ResponseThe major goals of this project are to discover pharmacogenomic predictors of breast cancer patient’s response to and toxicity from endocrine therapy. Role: Co-investigator (9% effort)5KL2RR024987 (PI: Thomas P. Shanley) 6/1/2015-5/31/2017MICHR KL2 Career Development Award (Awarded to Daniel L Hertz) $210,665Title of Project: Identification of neuropathy predictors for individualized paclitaxel treatmentThe major goals of this project are to define the association between cumulative paclitaxel exposure and neuropathy development to assist in development of tools for personalized dosing and to provide mentored experiential training to the PI.Role: Awardee (75% effort)No Number Assigned 1/1/2016-12/31/2016AACP New Investigator Award $10,000Title of Project: Identification of pharmacogenetic predictors of endocrine treatment for breast cancerThe major goals of this project are to discover the genetic variants responsible for determining concentrations of anastrozole and fulvestrant in post-menopausal patients with metastatic estrogen-receptor positive metastatic breast cancer. Role: PI (0% effort)PENDINGNo Number (PI: Daniel L Hertz) 3/1/2016-2/28/2017 0 CMHope Foundation $40,000 annual/total direct costsKinetic and genetic predictors of estradiol depletion in SWOG0226Role: PIR01 (PI: Ellen Lavoie-Smith) 9/1/2016-8/31/2021 0.36 CM YR 5 onlyNIH $17,469 (year 5 direct costs only)Duloxetine Plus an On-Line Cognitive Behavioral Program For Painful Chemotherapy-Induced Peripheral NeuropathyRole: co-InvestigatorR01 (PI: James M. Rae) 9/1/2016-8/31/2021 1.2 CM NIH $56,141 TOTAL direct costs = $11,228 average annual direct costsDuloxetine Plus an On-Line Cognitive Behavioral Program For Painful Chemotherapy-Induced Peripheral NeuropathyRole: co-InvestigatorInvited Presentations |
| National2014GWAS of Taxane-Induced Neuropathy in CALGB Clinical Trials. Alliance PPP Committee. Nov 7, 2014Application of Pharmacogenomics to Minimize Chemotherapy Toxicity. Education Session: Pharmacogenomics in the Era of Next Generation Sequencing. American Society of Clinical Oncology 2014 Annual MeetingPharmacogenetics of docetaxel toxicity in CALGB/Alliance 90401. Alliance GU Committee. May 10, 20142013Neutropenia Pharmacogenetics in Prostate Cancer (CALGB 90401). Alliance PPP Committee. March 13, 20132012Pharmacogenomics: Translation and Implementation. 31st NSGC Annual Education Conference Oct 26, 2012Neuropathy Pharmacogenomics in Prostate Cancer (CALGB 90401). PGRN-RIKEN Collaboration Meeting Oct 4, 2012, CALGB PPP Committee Nov 15, 2012Local/State2015Identification of neuropathy predictors for individualized paclitaxel treatment. University of Michigan MICHR CTSA External Advisory Board Meeting October 23, 2015Personalizing Paclitaxel Treatment in Breast Cancer Patients. University of Michigan CanSORT Project Team Meeting April 28, 20152013A genome-wide association study of docetaxel-induced peripheral neuropathy in CALGB 90401. University of Michigan Hematology/Oncology Research Conference, May 23, 2013Germline Pharmacogenetics in Cancer: Recognizing the Forgotten Genome. University of Michigan/Hematology/Oncology Research Conference, May 2, 2013Germline Genetic Predictors of Paclitaxel Efficacy and Toxicity. University of Michigan Translational Breast Cancer Symposium, April 17, 2013Pharmacogenetic Predictors of Paclitaxel Response and Toxicity in Breast Cancer Patients. Breast Spore Meeting, Jan 22, 2013Discovery and Validation of Pharmacogenetic Predictors of Taxane-induced Peripheral Neuropathy, Graduate Dissertation Defense, Jan 4, 20132012Discovery and Validation of Pharmacogenetic Markers of Paclitaxel-Induced Peripheral Neuropathy. Gentris Corp, Oct 24, 2012Pharmacogenetics of Paclitaxel-Induced Neuropathy, Perou Lab Meeting, Sept 27, 2012Patients Carrying CYP2C8\*3 are at Increased Risk of Paclitaxel-induced Neuropathy, UNC Eshelman School of Pharmacy Graduate Program Retreat, Aug 20, 20122011The Influence of Polymorphisms in Drug Exposure Genes on the Risk of Severe Paclitaxel-induced Neuropathy, Division of Pharmacotherapy and Experimental Therapeutics Seminar, Nov 15, 20112010Genetic Predictors of Taxane Treatment Outcomes, Division of Pharmacotherapy and Experimental Therapeutics Seminar, March 23, 2010Prior to 2010Creation of a Murine Mammary Carcinoma Model to Test Metronomic Delivery of a Chemotherapeutic Agent, Ernest Mario School of Pharmacy Honors Program Symposium, April 26, 2007Synthesis of PTTP Semi-Conducting Organic Layer for a Thin Film Transistor, IGERT Summer Undergraduate Research Fellowship Symposium, Aug 12, 2004 |
| Teaching and Mentoring |
| University of Michigan  |
| *College of Pharmacy Teaching* |
| 2014-Present | Therapeutics Problem Solving (Pharmacy 432)Guest lecturer, Drug Interactions and Therapeutic Drug MonitoringPharmaceutical Sciences (Pharmacy 563)Guest lecturer, Germline Genetic Testing in Oncology and Race/Gender in Pharmacogenetics  |
| *Pharm D Investigation Students*: |
| 2016-Present2015-Present2014-Present | Andrew Glatz, Katherine YangEmily Van Wieren, Holly Reed, Andrew Nobani, Lauren MarcathWilliam Danko, Hugh Nguyen |
| *Other Research Mentees* |
| 2015-Present2014-Present | Kiran Vangipuram (UM COP Student)Alisah Vora (UM Undergraduate Student) |
| University of North carolina |
| *UNC Eshelman School of Pharmacy Teaching* |
| 201220112010 | Quantitative Methods in Clinical Research (DPET 831)Guest lecturer, Statistics in Pharmacogenetics Lecture and Recitation ActivityScience and Methods in Drug Development (DPET 841)Course Development TeamSuper Teaching Assistant (DPET 831)Recitation Developer and Instructor  |
| *Research mentees* |
| 2012 | Stefanie D Krens, Visiting Scholar, University of Utrecht |
| Service to the University of Michigan College of Pharmacy |
| 2013-Present | Member, Academic Integrity Task ForceMember, PharmD Investigations CommitteeMember, Faculty Development CommitteeOther: Faculty Mentor for 2 Pharmacy Phamilies, Faculty Chaperone for PharmD Student Smoking Cessation Outreach Project (2014), PharmD Patient Counseling Competition Patient, Faculty Auction, PharmD Student Interviews, Dean Candidate Interview Dinner, Volunteer Patient for P1 Laboratory Activity, Pharmacogenomics Working Group (2014-2015) |
| Professional Service |
| Professional Society Memberships |
| 2014-Present2013-Present2012-Present | Affiliate Member Pharmacogenomics Research Network (PGRN)Inter-group Drug Interactions Task Force Committee ChairSouthwest Oncology Group (SWOG), Breast Cancer Translational Working Group, Drug Information Committee, Pharmacist Liaison to Cancer Control & Lung CommitteesPharmacogenomics Knowledge Bank (PharmGKB)Clinical Pharmacogenetics Implementation Consortium (CPIC)American Society for Clinical Oncology (ASCO)Alliance for Clinical Trials in Oncology, Pharmacogenomics and Population Pharmacokinetics Committee Cadre Member, Peripheral Neuropathy Working Group |
| Ad hoc Journal referee (alphabetical):Annals of OncologyBMC Medical GenomicsBreast Cancer Research and TreatmentBritish Journal of Clinical PharmacologyCancer Chemotherapy and PharmacologyCancer Control: Journal of the Moffitt Cancer CenterCancer Treatment ReviewsClinical Cancer ResearchClinical Pharmacology & TherapeuticsCurrent Drug SafetyGenesJournal of Clinical Oncology Molecular Cancer TherapeuticsMolecular Diagnosis and TherapyPharmaceutical ResearchPharmacogenetics and GenomicsPharmacogenomicsPharmacogenomics and Personalized MedicinePharmacotherapyPLOS OneThe Annals of PharmacotherapyGrant Review:Welcome TrustAmerican Foundation of Pharmaceutical Education |
| Awards and Honors |
| 20152013201220112010200920082007200620052004 | MICHR K Mentored Clinical Scientist Career Development AwardGraduate Education Advancement Board Impact AwardAmerican Association of Cancer Research Scholar-In-TrainingCancer Institute of New Jersey Young Philanthropist AwardAFPE Pre-Doctoral Fellowship Competitive RenewalAFPE Pre-Doctoral Fellowship Excellence in Teaching/Instruction Assistance AwardErnest Mario School of Pharmacy Honors Program GraduateCell Biology Achievement AwardRho Chi-AFPE First Year Graduate ScholarshipMartin Daffner Endowed ScholarshipNew Jersey Center for Biomaterials Summer Research FellowshipJohn & Josephine Calasibetta ScholarshipRho Chi National Pharmacy Honor Society InducteeNovarits-AFPE Gateway to Research ScholarshipMartin Daffner Endowed ScholarshipPharmacy Alumni Association Scholarship“Knight In Shining Armor” Award for Student InvolvementEric D. Siefert ScholarshipIGERT-Summer Undergraduate Research Fellowship |